Engineering the best transplant outcome for high-risk acute myeloid leukemia : the donor, the graft and beyond
Copyright © 2023 International Society for Cell & Gene Therapy. All rights reserved..
Allogeneic hemopoietic cell transplantation remains the goal of therapy for high-risk acute myeloid leukemia (AML). However, treatment failure in the form of leukemia relapse or severe graft-versus-host disease remains a critical area of unmet need. Recently, significant progress has been made in the cell therapy-based interventions both before and after transplant. In this review, the Stem Cell Engineering Committee of the International Society for Cell and Gene Therapy summarizes the literature regarding the identification of high risk in AML, treatment approaches before transplant, optimal transplant platforms and measures that may be taken after transplant to ideally prevent, or, if need be, treat AML relapse. Although some strategies remain in the early phases of clinical investigation, they are built on progress in pre-clinical research and cellular engineering techniques that are already improving outcomes for children and adults with high-risk malignancies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Cytotherapy - (2023) vom: 04. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Belbachir, Safia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute myeloid leukemia |
|---|
| Anmerkungen: |
Date Revised 06.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.jcyt.2023.11.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365458309 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365458309 | ||
| 003 | DE-627 | ||
| 005 | 20231226101717.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcyt.2023.11.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1218.xml |
| 035 | |a (DE-627)NLM365458309 | ||
| 035 | |a (NLM)38054912 | ||
| 035 | |a (PII)S1465-3249(23)01103-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Belbachir, Safia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Engineering the best transplant outcome for high-risk acute myeloid leukemia |b the donor, the graft and beyond |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 International Society for Cell & Gene Therapy. All rights reserved. | ||
| 520 | |a Allogeneic hemopoietic cell transplantation remains the goal of therapy for high-risk acute myeloid leukemia (AML). However, treatment failure in the form of leukemia relapse or severe graft-versus-host disease remains a critical area of unmet need. Recently, significant progress has been made in the cell therapy-based interventions both before and after transplant. In this review, the Stem Cell Engineering Committee of the International Society for Cell and Gene Therapy summarizes the literature regarding the identification of high risk in AML, treatment approaches before transplant, optimal transplant platforms and measures that may be taken after transplant to ideally prevent, or, if need be, treat AML relapse. Although some strategies remain in the early phases of clinical investigation, they are built on progress in pre-clinical research and cellular engineering techniques that are already improving outcomes for children and adults with high-risk malignancies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a T cell depletion | |
| 650 | 4 | |a acute myeloid leukemia | |
| 650 | 4 | |a novel cellular therapies | |
| 700 | 1 | |a Abraham, Allistair |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Akshay |e verfasserin |4 aut | |
| 700 | 1 | |a Prockop, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a DeZern, Amy E |e verfasserin |4 aut | |
| 700 | 1 | |a Bonfim, Carmem |e verfasserin |4 aut | |
| 700 | 1 | |a Bidgoli, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jinjing |e verfasserin |4 aut | |
| 700 | 1 | |a Ruggeri, Annalisa |e verfasserin |4 aut | |
| 700 | 1 | |a Bertaina, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Boelens, Jaap Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Purtill, Duncan |e verfasserin |4 aut | |
| 700 | 0 | |a Stem Cell Engineering Committee of the International Society for Cell and Gene Therapy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cytotherapy |d 1999 |g (2023) vom: 04. Dez. |w (DE-627)NLM118333852 |x 1477-2566 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:04 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcyt.2023.11.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 04 |c 12 | ||